Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1048 | Convalescent Plasma (CP) Wiki | 0.71 |
| drug4628 | observational Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
Description: Safety of convalescent plasma for pediatric patients will be determined by capturing the grade 3-5 adverse events that are possible, probably or definitely related to the CP infusion, defined using the NCI Common Terminology Criteria for Adverse Events (CTCAE)
Measure: Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion Time: 28 daysDescription: Change in percent of supplemental oxygen within 72 hours after infusion
Measure: Change in percent of supplemental oxygen Time: Baseline, 72 hours after infusionDescription: Number of patients that required change in level of respiratory support such as nasal canula, non-invasive ventilation, mechanical ventilation, high frequency oscillator ventilation, and extracorporeal membrane oxygenation (ECMO)
Measure: Number of patients that required change in level of respiratory support Time: Baseline, 72 hours after infusionDescription: Number of deaths
Measure: Mortality Time: up to 1 yearDescription: Length of ICU stay (days) will be recorded
Measure: Mean length of ICU stay (days) Time: Up to 28 daysDescription: Length of hospital stay (days) will be recorded
Measure: Mean length of hospital stay (days) Time: Up to 28 daysDescription: Length of ventilation (days) will be recorded
Measure: Mean length of ventilation (days) Time: Up to 28 daysDescription: Number of patients with progression to renal dysfunction and/or multisystem organ failure will be recorded
Measure: Number of patients with progression to renal dysfunction and/or multisystem organ failure Time: up to 1 yearDescription: Cytokine milieu will be assayed by Luminex
Measure: IL-6 level Time: up to 28 daysDescription: Cellular studies will be used for evaluation of anti-SARS CoV 2 specific T cells
Measure: Number of anti-SARS CoV 2 specific T cells Time: up to 28 daysDescription: Cellular studies will be used for evaluation of diversity of circulating T cells
Measure: Diversity of circulating T cells Time: up to 28 daysDescription: Antibody titers to SARS-CoV-2 evaluation will be performed in vivo
Measure: ARS-CoV-2 Antibody Titer Time: up to 28 daysDescription: Neutralizing antibodies are a type of virus specific antibody that not only bind virus but bind in a manner that prevents viral infection. Test will be will be performed in vivo.
Measure: SARS-CoV-2 Neutralizing Titer Time: up to 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports